Varicella-zoster virus: Pathogenesis, immunity, and clinical management inhematopoietic cell transplant recipients

Authors
Arvin, AM
Citation
Am. Arvin, Varicella-zoster virus: Pathogenesis, immunity, and clinical management inhematopoietic cell transplant recipients, BIOL BLOOD, 6(3), 2000, pp. 219-230
Citations number
71
Categorie Soggetti
Hematology
Journal title
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
ISSN journal
10838791 → ACNP
Volume
6
Issue
3
Year of publication
2000
Pages
219 - 230
Database
ISI
SICI code
1083-8791(2000)6:3<219:VVPIAC>2.0.ZU;2-E
Abstract
New information about the mechanisms of varicella-zoster virus (VZV) pathog enesis and the host response to the virus has improved our understanding of the threat that VZV reactivation may pose after hematopoietic cell transpl antation (HCT). Antiviral therapy compensates for some of the deficiencies in VZV immunity in HCT recipients, and inactivated varicella vaccine may be useful for the early reconstitution of adaptive immunity to VZV after HCT.